Cutler Group’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q4 | – | Sell |
-17,800
| Closed | -$330K | – | 4576 |
|
|
2023
Q3 | $330K | Sell |
17,800
-100
| -0.6% | -$1.13K | 0.03% | 566 |
|
|
2023
Q2 | $197K | Hold |
17,900
| – | – | 0.03% | 618 |
|
|
2023
Q1 | $240K | Sell |
17,900
-85
| -0.5% | -$1.47K | 0.02% | 607 |
|
|
2022
Q4 | $222K | Sell |
17,985
-2,211
| -11% | -$31.3K | 0.02% | 745 |
|
|
2022
Q3 | $281K | Buy |
20,196
+6,111
| +43% | +$98.4K | 0.02% | 807 |
|
|
2022
Q2 | $194K | Sell |
14,085
-4,371
| -24% | -$70K | 0.01% | 1030 |
|
|
2022
Q1 | $300K | Buy |
18,456
+10,256
| +125% | +$161K | 0.02% | 943 |
|
|
2021
Q4 | $133K | Sell |
8,200
-1,100
| -12% | -$18.5K | 0.01% | 1636 |
|
|
2021
Q3 | $138K | Sell |
9,300
-100
| -1% | -$1.6K | 0.01% | 1652 |
|
|
2021
Q2 | $187K | Sell |
9,400
-400
| -4% | -$7.93K | 0.01% | 1392 |
|
|
2021
Q1 | $226K | Buy |
9,800
+7,700
| +367% | +$215K | 0.01% | 1189 |
|
|
2020
Q4 | $51K | Sell |
2,100
-3,400
| -62% | -$113K | ﹤0.01% | 2011 |
|
|
2020
Q3 | $228K | Buy |
+5,500
| New | +$253K | 0.01% | 854 |
|
|
2020
Q2 | – | Sell |
-2,400
| Closed | -$185K | – | 5049 |
|
|
2020
Q1 | $151K | Buy |
2,400
+800
| +50% | +$71.9K | 0.01% | 1116 |
|
|
2019
Q4 | $198K | Buy |
1,600
+1,260
| +371% | +$113K | 0.01% | 828 |
|
|
2019
Q3 | $22K | Sell |
340
-460
| -58% | -$30.9K | ﹤0.01% | 2132 |
|
|
2019
Q2 | $63K | Buy |
800
+600
| +300% | +$53.7K | 0.01% | 1381 |
|
|
2019
Q1 | $22K | Sell |
200
-1,250
| -86% | -$137K | ﹤0.01% | 2002 |
|
|
2018
Q4 | $146K | Buy |
+1,450
| New | +$150K | 0.01% | 809 |
|
|
2018
Q3 | – | Sell |
-1,990
| Closed | -$211K | – | 4868 |
|
|
2018
Q2 | $166K | Buy |
1,990
+1,190
| +149% | +$87.1K | 0.01% | 867 |
|
|
2018
Q1 | $49K | Buy |
800
+600
| +300% | +$36.2K | ﹤0.01% | 1682 |
|
|
2017
Q4 | $11K | Sell |
200
-2,245
| -92% | -$142K | ﹤0.01% | 3075 |
|
|
2017
Q3 | $141K | Sell |
2,445
-3,756
| -61% | -$405K | 0.01% | 1409 |
|
|
2017
Q2 | $750K | Sell |
6,201
-75
| -1% | -$8.69K | 0.03% | 514 |
|
|
2017
Q1 | $709K | Sell |
6,276
-16,625
| -73% | -$1.94M | 0.03% | 509 |
|
|
2016
Q4 | $2.49M | Buy |
22,901
+8,535
| +59% | +$1.02M | 0.09% | 169 |
|
|
2016
Q3 | $2.36M | Buy |
14,366
+10,116
| +238% | +$1.59M | 0.11% | 141 |
|
|
2016
Q2 | $606K | Sell |
4,250
-653
| -13% | -$95.2K | 0.03% | 493 |
|
|
2016
Q1 | $629K | Buy |
4,903
+253
| +5% | +$29.9K | 0.04% | 432 |
|
|
2015
Q4 | $694K | Buy |
+4,650
| New | +$787K | 0.04% | 473 |
|
Cutler Group's ICPT Position: Q4 2023 in Review
Cutler Group sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2023, closing a stake of 17,800 shares — an estimated $330K sold.
Cutler Group first reported a position in ICPT in Q4 2015 and held it in 30 quarters. The position peaked at $2.49M in Q4 2016. 0 funds tracked by Wall St. Rank hold ICPT as of Q4 2023.
- Cutler Group reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2023 after selling out during the quarter.
- Cutler Group sold 17,800 Intercept Pharmaceuticals, Inc. shares in Q4 2023, an estimated $330K.
- Cutler Group first reported a position in Intercept Pharmaceuticals, Inc. in Q4 2015 and held it in 30 quarters.
- Cutler Group's Intercept Pharmaceuticals, Inc. position peaked at $2.49M in Q4 2016.
- 0 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2023.
Based on Cutler Group's 13F filing for Q4 2023, filed 18 Jan 2024.